Literature DB >> 7660082

Serological screening for toxoplasmosis in pregnancy in Slovenia.

J Logar1, Z Novak-Antolic, A Zore.   

Abstract

In the period from 1981 to 1994, serological screening for toxoplasmosis was carried out in 20,953 pregnant women in Slovenia. Seropositivity among pregnant women was found to have decreased from 52% in the 1980s to 37% in the recent period, 1991-94, while during the same period the incidence of suspected primary infections acquired in pregnancy rose from 0.33% to 0.75%. These latest figures ought to promote an informed debate on the possible need for obligatory serological screening of pregnant women in Slovenia for toxoplasmosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7660082     DOI: 10.3109/00365549509018999

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  5 in total

1.  Prevalence of antibodies to Toxoplasma gondii in the female population of the County of Split Dalmatia, Croatia.

Authors:  V Punda-Polić; M Tonkić; V Capkun
Journal:  Eur J Epidemiol       Date:  2000       Impact factor: 8.082

Review 2.  Kinetics of Toxoplasma infection in the Balkans.

Authors:  Branko Bobić; Aleksandra Nikolić; Ivana Klun; Olgica Djurković-Djaković
Journal:  Wien Klin Wochenschr       Date:  2011-09-22       Impact factor: 1.704

Review 3.  Toxoplasma gondii: from animals to humans.

Authors:  A M Tenter; A R Heckeroth; L M Weiss
Journal:  Int J Parasitol       Date:  2000-11       Impact factor: 3.981

4.  Risk factors for Toxoplasma infection in a reproductive age female population in the area of Belgrade, Yugoslavia.

Authors:  B Bobić; I Jevremović; J Marinković; D Sibalić; O Djurković-Djaković
Journal:  Eur J Epidemiol       Date:  1998-09       Impact factor: 8.082

5.  Congenital toxoplasmosis: an in-depth density-equalizing mapping analysis to explore its global research architecture.

Authors:  Dörthe Brüggmann; Vanessa Handl; Doris Klingelhöfer; Jenny Jaque; David A Groneberg
Journal:  Parasit Vectors       Date:  2015-12-21       Impact factor: 3.876

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.